News

As per the agreement, CrystalGenomics is expected to receive research funding from AstraZeneca for two years. CrystalGenomics will also be eligible to receive future milestones and royalty payments

Using Kenta’s proprietary hybridoma cell line, Rentschler will develop a manufacturing process for the former’s KBSA301 antibody using, for the first time, single-use bioreactor technology. Nikolaus Rentschler, chief

Reportedly, the APC’s team of pharmacovigilance experts provide a complete range of services using the latest technology. The service is based on a fully electronic platform which is

The decision was based on results from the clinical trial, OGT 918-007, and two multicenter NP-C disease cohort studies and clinical trials in related lysosomal storage disorders for

Franz Groiss, in-charge of managing clinical studies at Avir, said: “In double blind studies, neither the administering physician (and/or the commissioning party) nor the volunteers know who gets

Sirnaomics is developing nanoparticle-based siRNA delivery systems in three generations: the self-assembled nanoparticles, ligand-directed nanoparticles, and infrared-activated nanoparticles, for various types of therapeutic applications. Patrick Lu, president and

Rapiacta, licensed from US-based BioCryst Pharmaceuticals, has been developed by Shionogi in Japan. Shionogi received approval for both single dose administration for adult uncomplicated seasonal influenza infection as

The company said that its new formulation plant is likley to deliver products to over 15 countries. Pharmabiz quoted, Archana Mitra, associate vice president of exports at Bal

Reportedly, under the purchase order, Sinovac is required to deliver an additional 8.57 million doses of Panflu1 (15ug/0.5ml) to the Chinese Central Government, of which 2.33 million doses